ONCOLOGY Nurse Edition October 2008, Vol 22 No 11

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

The use of CAR T-cell therapy and other sequencing options were discussed for patients with multiple myeloma.

“How do we personalize and improve patient selection for frontline treatment now that patients are living, on average, more than 2 years with this aggressive cancer?” said David H. Aggen, MD, PhD